Citigroup
STLN

Citigroup’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Citigroup’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Buy
35,747
+31,565
+755% +$133K ﹤0.01% 4359
2026
Q1 		$12.8K Buy
4,182
+2,431
+139% +$7.45K ﹤0.01% 4951
2025
Q4 		$6.23K Sell
1,751
-799
-31% -$2.96K ﹤0.01% 5183
2025
Q3 		$8.9K Sell
2,550
-18,410
-88% -$63.1K ﹤0.01% 5060
2025
Q2 		$43K Buy
20,960
+20,957
+698,567% +$52.4K ﹤0.01% 4847
2025
Q1 		$3 Sell
3
-631
-100% -$489 ﹤0.01% 5513
2024
Q4 		$196 Buy
634
+609
+2,436% +$158 ﹤0.01% 5666
2024
Q3 		$8 Sell
25
-15
-38% -$6 ﹤0.01% 5628
2024
Q2 		$18 Sell
40
-12,814
-100% -$10.9K ﹤0.01% 5497
2024
Q1 		$20.3K Buy
12,854
+12,356
+2,481% +$23.5K ﹤0.01% 5027
2023
Q4 		$1.02K Hold
498
– – ﹤0.01% 5465
2023
Q3 		$697 Hold
498
– – ﹤0.01% 5157
2023
Q2 		$274 Buy
+498
New +$263 ﹤0.01% 5415
2023
Q1 		– Sell
-235
Closed -$388 – 5860
2022
Q4 		$388 Sell
235
-294
-56% -$825 ﹤0.01% 5537
2022
Q3 		$2K Sell
529
-608
-53% -$3.58K ﹤0.01% 5537
2022
Q2 		$6K Buy
+1,137
New +$8.28K ﹤0.01% 5569

Other funds holding STLN

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IAAG
Innovative Asset Advisors Group Shelton, Connecticut $229M AUM

Citigroup's STLN Position: Q2 2026 in Review

Citigroup increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 755% in Q2 2026, buying an estimated $133K and bringing the position to 35,747 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #4359.

Citigroup first reported a position in STLN in Q2 2022 and has held it in 16 quarters since. 29 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Citigroup held 35,747 shares of Starling Oncology Institute, Inc. Common Stock worth $194K as of Q2 2026.
  • Citigroup bought 31,565 Starling Oncology Institute, Inc. Common Stock shares in Q2 2026, an estimated $133K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4359 holding.
  • Citigroup first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2022 and has held it in 16 quarters since.
  • 29 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.